ITM to Unveil Key Radiopharma Data for Pancreatic Neuroendocrine Tumors

GARCHING, GERMANY – February 25, 2026 – ITM Isotope Technologies Munich SE, a prominent player in the radiopharmaceutical space, is poised to shed new light on the treatment of pancreatic neuroendocrine tumors (pNETs). The company announced today it will present a detailed post-hoc subgroup analysis from its pivotal Phase 3 COMPETE trial at the upcoming 23rd Annual European Neuroendocrine Tumor Society (ENETS) Conference in Kraków, Poland.

The presentation, scheduled for March 5, will focus specifically on the efficacy of its investigational agent, 177Lu-edotreotide (ITM-11), within the pNET patient population. This deep dive follows the trial's successful primary endpoint readout, which demonstrated a clinically and statistically significant improvement in progression-free survival (PFS) for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared to the current standard-of-care therapy, everolimus. As ITM moves closer to a potential regulatory decision in the United States, this granular data could be crucial in defining the future role of 177Lu-edotreotide in a complex and evolving treatment landscape.

A Sharper Focus on a Challenging Cancer

Pancreatic neuroendocrine tumors are a rare and notoriously heterogeneous group of cancers originating in the hormone-producing islet cells of the pancreas. While some are slow-growing, others can be aggressive and metastasize, posing significant treatment challenges. For patients with inoperable or advanced disease, options are aimed at controlling tumor growth and managing symptoms, but curative therapies remain elusive.

The current standard of care includes somatostatin analogs (SSAs), targeted molecular therapies such as everolimus and sunitinib, and for some, chemotherapy. The field was significantly advanced by the approval of peptide receptor radionuclide therapy (PRRT) with lutetium-177 dotatate, which established targeted radiation as a powerful tool for somatostatin receptor-positive tumors.

ITM's COMPETE trial sought to build on this foundation by directly comparing its next-generation radiopharmaceutical, 177Lu-edotreotide, against everolimus in 309 patients with Grade 1 or Grade 2 GEP-NETs. The overall results were compelling: patients receiving 177Lu-edotreotide experienced a median progression-free survival of 23.9 months, a significant extension compared to the 14.1 months observed in the everolimus arm. The therapy also showed a substantially higher objective response rate (21.9% vs. 4.2%).

While these top-line results were strong, the upcoming ENETS presentation promises a more nuanced picture. By isolating and analyzing the data specifically for pNET patients, ITM aims to provide clinicians with a clearer understanding of the therapy’s benefit in this distinct subgroup. Initial data had shown a positive trend in pNETs, and this new exploratory analysis is expected to provide deeper insights that could further bolster the case for 177Lu-edotreotide as a tailored option for this difficult-to-treat cancer.

Navigating a Competitive Radiopharma Landscape

The announcement comes at a time of intense activity and optimism in the radiopharmaceutical sector. The commercial success of Novartis's Lutathera (lutetium-177 dotatate) has validated the PRRT approach for NETs and fueled a wave of investment and innovation. For a new agent like 177Lu-edotreotide to carve out a significant market share, clear differentiation is key.

ITM's strategic approach appears to be multi-faceted. First, the design of the COMPETE trial itself offers a powerful talking point. By conducting a head-to-head comparison against an active and widely used targeted therapy, ITM has generated robust data that directly addresses a relevant clinical question for oncologists. This contrasts with earlier trials that often compared PRRT against less active comparators.

Second, the company highlights the composition of its product. 177Lu-edotreotide utilizes non-carrier-added (n.c.a.) lutetium-177, which boasts a higher level of isotopic purity. While the direct clinical impact of this distinction requires further long-term evaluation, it is positioned as a potential advantage that could contribute to a more favorable efficacy and safety profile.

Finally, ITM is not limiting its ambitions to the patient population studied in COMPETE. The company is also running the COMPOSE trial, a Phase 3 study evaluating 177Lu-edotreotide in patients with more aggressive Grade 2 and Grade 3 GEP-NETs. Success in this area would address a significant unmet need and expand the therapy’s potential application into a patient group with fewer effective options, further distinguishing it in the market.

The Power of Precision: Why Subgroup Data Matters

Beyond its commercial implications, ITM's focus on the pNET subgroup underscores a fundamental shift in modern oncology toward precision medicine. Broad clinical trial results are no longer sufficient; the medical community now demands granular data that can guide treatment decisions for individual patients.

"Subgroup analyses are no longer a 'nice-to-have'; they are fundamental to understanding who benefits most from a new therapy," said one oncology analyst who follows the sector. "For rare, diverse cancers like NETs, this kind of data is gold. It helps clinicians move beyond a one-size-fits-all approach and tailor treatments for better outcomes."

This move toward personalization is critical for both efficacy and safety. By identifying the patient populations most likely to respond, physicians can maximize the benefit of a potent therapy while sparing non-responders from potential side effects and costs. The data from the pNET subgroup analysis, therefore, represents more than just an academic exercise; it is a vital component in the translation of a promising drug into a refined clinical tool.

The Path to Patients: Regulatory Hurdles and Market Access

The timing of the ENETS presentation is particularly significant given ITM's progress with regulators. The U.S. Food and Drug Administration (FDA) has already accepted the company's New Drug Application (NDA) for 177Lu-edotreotide and assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2026. The therapy also benefits from both Orphan Drug and Fast Track designations, which are designed to expedite the development and review of treatments for serious conditions with unmet needs.

With a regulatory decision on the horizon, the focus will increasingly shift to market access and reimbursement. Approval is only the first step; securing coverage from payers requires a compelling value proposition. The detailed efficacy and safety data from specific, hard-to-treat populations like pNET patients will be a cornerstone of that argument.

ITM's symposium at the ENETS conference, featuring leading experts in the field, further signals its intent to educate the clinical community and build a strong foundation for the therapy's potential launch. As the oncology world turns its attention to Kraków, the data presented could play a pivotal role in shaping the future standard of care for thousands of patients battling neuroendocrine tumors. The upcoming presentation is therefore not just a scientific update, but a critical step in the therapy's journey from clinical trial to clinical practice.